| HOME >> BIOLOGY >> TECHNOLOGY |
0% convertible preferred stock,
Series A no par value; no shares issued
and outstanding at December 31, 2007
and 500 shares issued and outstanding
at December 31, 2006 - 500,000
10% convertible preferred stock,
Series B no par value; no shares issued
and outstanding at December 31, 2007
and 2,082 shares issued and outstanding
at December 31, 2006 - 2,082,000
Common stock: $.01 par value; 60,000,000
authorized shares 10,104,719 issued at
December 31, 2007 and 7,882,074 issued
at December 31, 2006 101,046 78,820
Capital in excess of par value 15,320,771 11,926,815
Accumulated deficit (7,694,068) (9,335,982)
7,727,749 5,251,653
Less - Common stock in treasury, at cost
(4,600 shares) (14,950) (14,950)
Total Shareholders' Equity 7,712,799 5,236,703
Total Liabilities & Shareholders'
Equity $16,077,947 $15,316,260
PHOTONIC PRODUCTS GROUP, INC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Years Ended December 31,
2007 2006 2005
Revenues
Net sales $15,099,878 $13,921,127 $13,785,057
Cost and expenses
Cost of goods sold 9,141,049 9,377,313 9,956,125
Selling, general and
administrative expense 3,561,570 3,627,244 3,450,224
Internal research and
development expense - - 20,279
'/>"/>
| SOURCE Photonic Products Group, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Professor Straufs research is Nature Photonics’ cover article
2. 3-D photonic crystals will revolutionize telecommunications
3. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
4. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
5. Live Demos With Hydrogen, New Fuel Cell Products
6. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
7. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
8. iCAD to Feature New Products and Capabilities at European Congress of Radiology
9. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
10. China Biologic Products Commences Trading on OTC Bulletin Board
11. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |